|
|
|
|
HDAC4-Myogenin Axis As an Important Marker of HD-Related Skeletal Muscle Atrophy
|
|
|
|
|
|
|
|
نویسنده
|
mielcarek m. ,toczek m. ,smeets c.j.l.m. ,franklin s.a. ,bondulich m.k. ,jolinon n. ,muller t. ,ahmed m. ,dick j.r.t. ,piotrowska i. ,greensmith l. ,smolenski r.t. ,bates g.p.
|
|
منبع
|
plos genetics - 2015 - دوره : 11 - شماره : 3
|
|
چکیده
|
Skeletal muscle remodelling and contractile dysfunction occur through both acute and chronic disease processes. these include the accumulation of insoluble aggregates of misfolded amyloid proteins that is a pathological feature of huntington’s disease (hd). while hd has been described primarily as a neurological disease,hd patients’ exhibit pronounced skeletal muscle atrophy. given that huntingtin is a ubiquitously expressed protein,skeletal muscle fibres may be at risk of a cell autonomous hd-related dysfunction. however the mechanism leading to skeletal muscle abnormalities in the clinical and pre-clinical hd settings remains unknown. to unravel this mechanism,we employed the r6/2 transgenic and hdhq150 knock-in mouse models of hd. we found that symptomatic animals developed a progressive impairment of the contractile characteristics of the hind limb muscles tibialis anterior (ta) and extensor digitorum longus (edl),accompanied by a significant loss of motor units in the edl. in symptomatic animals,these pronounced functional changes were accompanied by an aberrant deregulation of contractile protein transcripts and their up-stream transcriptional regulators. in addition,hd mouse models develop a significant reduction in muscle force,possibly as a result of a deterioration in energy metabolism and decreased oxidation that is accompanied by the re-expression of the hdac4-dach2-myogenin axis. these results show that muscle dysfunction is a key pathological feature of hd. © 2015 mielcarek et al.
|
|
|
|
|
آدرس
|
department of medical and molecular genetics,king’s college london,london, United Kingdom, department of biochemistry,medical university of gdansk,gdansk, Poland, department of medical and molecular genetics,king’s college london,london,united kingdom,department of genetics,university of groningen,university medical center,groningen,groningen, Netherlands, department of medical and molecular genetics,king’s college london,london, United Kingdom, department of medical and molecular genetics,king’s college london,london, United Kingdom, department of medical and molecular genetics,king’s college london,london, United Kingdom, department of medical and molecular genetics,king’s college london,london,united kingdom,affimed therapeutics ag,heidelberg, Germany, sobell department of motor neuroscience and movement disorders and mrc centre for neuromuscular diseases,ucl institute of neurology,london, United Kingdom, sobell department of motor neuroscience and movement disorders and mrc centre for neuromuscular diseases,ucl institute of neurology,london, United Kingdom, mrc national institute for medical research,london, United Kingdom, sobell department of motor neuroscience and movement disorders and mrc centre for neuromuscular diseases,ucl institute of neurology,london, United Kingdom, department of biochemistry,medical university of gdansk,gdansk,poland,department of surgery and translational medicine,university of milano-bicocca,milano, Italy, department of medical and molecular genetics,king’s college london,london, United Kingdom
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Authors
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|